Literature DB >> 25115509

Comparison of different DNA extraction methods from peripheral blood cells: advice from the Fondazione Italiana Linfomi Minimal Residual Disease Network.

Claudia Mannu1, Anna Gazzola1, Elena Ciabatti2, Fabio Fuligni1, Marzia Cavalli3, Irene Della Starza3, Elisa Genuardi4, Barbara Mantoan4, Luigia Monitillo4, Ilaria Del Giudice3, Marco Ladetto4, Gianluca Gaidano5, Elena Sabattini1, Stefano A Pileri1, Sara Galimberti2, Pier Paolo Piccaluga1.   

Abstract

Genomic DNA extraction is a primary component of genomic research and diagnostic routine analysis. Recently, the importance of this process has been highlighted by the necessity to standardize the diagnostic procedure. In this regard, the Minimal Residual Disease (MRD) Network of the Fondazione Italiana Linfomi (FIL MRD Network) has performed a comparative study of four different commercially available kits for DNA extraction, applying them on a panel of cellular pellets, with the aim of defining possible technical recommendations in order to harmonize and standardize diagnostic procedures in the clinical setting. Overall, all four kits usually allowed the recovery of a significant quantity of high-quality DNA (in most conditions), although specific indications could be addressed for cellular pellets of different sizes.

Keywords:  DNA extraction; FIL MRD Network; PCR

Year:  2015        PMID: 25115509     DOI: 10.3109/10428194.2014.914199

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  1 in total

1.  The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study.

Authors:  Sara Galimberti; Elena Ciabatti; Giacomo Ercolano; Susanna Grassi; Francesca Guerrini; Nadia Cecconi; Martina Rousseau; Giulia Cervetti; Francesco Mazziotta; Lorenzo Iovino; Franca Falzetti; Flavio Falcinelli; Alberto Bosi; Luigi Rigacci; Sofia Kovalchuk; Daniele Vallisa; Lucia Macchia; Eugenio Ciancia; Mario Petrini
Journal:  Front Pharmacol       Date:  2017-06-29       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.